专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080261227A1 Kinetic Pcr Assay for Quantification of Gene Amplification on Chromosome 17 审中-公开
标题翻译：用于定量染色体17上的基因扩增的动力学Pcr测定
公开(公告)号：US20080261227A1
公开(公告)日：2008-10-23
申请号：US12093603
申请日：2006-11-28
申请人： Lu Ping Shen , Marc Munnes , Ralph Markus Wirtz , Daryn Kenny , Charlene E. Bush-Donovan
发明人： Lu Ping Shen , Marc Munnes , Ralph Markus Wirtz , Daryn Kenny , Charlene E. Bush-Donovan
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/16
摘要： Provided is a kinetic PCR (“kPCR”) assay for determining gene copy number of a target gene located on chromosome 17. The kPCR assay uses the MMP-28 gene located at the 17q11.2-17q12 loci as a control and thus, is capable of detecting gene copy number of any gene on chromosome 17 in both singleplex and multiplex format without the need for a standard curve. The kPCR assay is useful for determining the gene copy number of the HER2/neu gene located at loci 17q12-17q21.32, which is a requirement for determining if a breast cancer patient is a candidate for anti-HER2/neu gene therapy.
摘要翻译：提供了用于确定位于染色体17上的靶基因的基因拷贝数的动力学PCR（“kPCR”）测定.kPCR测定使用位于17q11.2-17q12位点的MMP-28基因作为对照，因此是能够以单一和多重格式检测染色体17上的任何基因的基因拷贝数，而不需要标准曲线。 kPCR测定可用于确定位于位点17q12-17q21.32处的HER2 / neu基因的基因拷贝数，这是确定乳腺癌患者是否为抗HER2 / neu基因治疗的候选者的要求。

2. 发明申请

US20110033852A1 PRESENT INVENTION RELATES TO METHODS FOR PREDICTION OF THE THERAPEUTIC SUCCESS OF BREAST CANCER THERAPY 审中-公开
标题翻译：本发明涉及用于预测乳腺癌治疗效果的方法
公开(公告)号：US20110033852A1
公开(公告)日：2011-02-10
申请号：US12745110
申请日：2008-11-14
申请人： Ralph Markus Wirtz , Karin Milde-Langosch , Maike Ihnen , Christine Schroder
发明人： Ralph Markus Wirtz , Karin Milde-Langosch , Maike Ihnen , Christine Schroder
IPC分类号： C12Q1/68 , C07K16/18 , C07H21/00 , A61K38/18
CPC分类号： G01N33/57442 , C12Q1/6886 , C12Q2600/106 , G01N33/57411 , G01N33/57415 , G01N33/57449 , G01N2333/485 , G01N2333/51 , G01N2333/70546 , G01N2333/96411 , G01N2800/52
摘要： The present invention relates to a method for predicting a clinical response of a patient suffering from or at risk of developing gynecologic cancer towards a given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining the expression level of at least one gene selected from the group comprising ALCAM, Osteopontin, Her-2/neu, EGFR, uPA/PAI-1 and/or ESR1, in particular of ALCAM and/or Osteopontin, in said sample; c) comparing the pattern of expression level (s) determined in (b) with one or several reference pattern (s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient or implementing therapeutic regimen in said patient from the outcome of the comparison in step (c).
摘要翻译：本发明涉及一种用于预测患有或处于发展妇科癌症风险的患者的临床反应朝向给定治疗方式的方法，所述方法包括以下步骤：a）从所述患者获得生物样品; b）确定所述样品中至少一种选自ALCAM，骨桥蛋白，Her-2 / neu，EGFR，uPA / PAI-1和/或ESR1，特别是ALCAM和/或骨桥蛋白的基因的表达水平 ; c）将（b）中确定的表达水平的模式与一种或多种表达水平的参考模式进行比较; 以及d）根据步骤（c）中的比较结果预测所述患者中所述给定治疗方式的治疗成功或实施所述患者的治疗方案。

3. 发明申请

US20080311567A1 Tumor Markers for Use in the Diagnosis of Colorectal Carcinomas and/or Metastases Originating Therefrom 审中-公开
标题翻译：肿瘤标志物用于诊断结肠直肠癌和/或转移起源于其中
公开(公告)号：US20080311567A1
公开(公告)日：2008-12-18
申请号：US11659250
申请日：2005-07-29
申请人： Wolfgang Michael Bruckl , Axel Wein , Marc Munnes , Ralph Markus Wirtz
发明人： Wolfgang Michael Bruckl , Axel Wein , Marc Munnes , Ralph Markus Wirtz
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
摘要： The invention relates to a method (i) for detecting a carcinoma, especially an adenocarcinoma, preferably a gastrointestinal carcinoma and more preferably a colorectal carcinoma, (ii) for predicting metastases, preferably liver metastases, depending on a primary colon carcinoma and/or (iii) for predicting the response of metastases to a 5-fluorouracil-containing chemotherapy. The inventive method comprises determining a gene expression profile of 120 marker genes or a selection thereof.
摘要翻译：本发明涉及一种用于检测癌症，特别是腺癌，优选胃肠癌，更优选结肠直肠癌的方法（i），（ii）根据原发性结肠癌和/或（...）的预测转移，优选肝转移， iii）预测转移至含有5-氟尿嘧啶的化疗的反应。本发明的方法包括确定120个标记基因的基因表达谱或其选择。

4. 发明申请

US20180251854A1 Method For Predicting Therapy Responsiveness In Basal Like Tumors 审中-公开
公开(公告)号：US20180251854A1
公开(公告)日：2018-09-06
申请号：US15913563
申请日：2018-03-06
申请人： Ralph Markus Wirtz , Ralf Kronenwett
发明人： Ralph Markus Wirtz , Ralf Kronenwett
IPC分类号： C12Q1/6886
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158
摘要： The present invention is related to a method for predicting a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining, on a non protein basis, the expression level of at least one gene of interest, said gene being correlated with the Estrogen receptor (ESR) status in the said sample, c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient from the outcome of the comparison in step (c).

5. 发明授权

US08519116B2 Method for predicting a clinical response of a patient suffering from or at risk of developing cancer towards a given mode of treatment 有权
标题翻译：用于预测患有或处于发生癌症风险的患者对于给定治疗方式的临床反应的方法
公开(公告)号：US08519116B2
公开(公告)日：2013-08-27
申请号：US12989969
申请日：2009-03-27
申请人： Ralph Markus Wirtz , Wolfgang Michael Bruckl
发明人： Ralph Markus Wirtz , Wolfgang Michael Bruckl
IPC分类号： C07H21/04 , C07H21/02 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112
摘要： The present invention relates to a method for predicting a clinical response of a patient suffering from or at risk of developing cancer, preferably colorectal cancer, towards a given mode of treatment, the method including the steps of: a) obtaining a biological sample from the patient; b) determining the expression level of at least SPON-2, and optionally determining the expression level of SPON-1, in the sample; c) comparing the expression level or expression levels determined in (b) with one or several reference expression levels; and d) predicting therapeutic success for the given mode of treatment in the patient or implementing therapeutic regimen in the patient from the outcome of the comparison in step (c).
摘要翻译：本发明涉及一种用于预测患有或具有发展癌症（优选结肠直肠癌）风险的患者对于给定治疗方式的临床反应的方法，所述方法包括以下步骤：a）从患者; b）确定至少SPON-2的表达水平，并且可选地确定样品中SPON-1的表达水平; c）将（b）中测定的表达水平或表达水平与一个或多个参考表达水平进行比较; 以及d）从步骤（c）中的比较结果预测患者给定治疗方式的治疗成功或实施患者的治疗方案。

6. 发明申请

US20080305962A1 Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies 审中-公开
标题翻译：预防治疗成功的方法和试剂盒，癌症治疗中的无复发和总体生存
公开(公告)号：US20080305962A1
公开(公告)日：2008-12-11
申请号：US11996680
申请日：2006-07-20
申请人： Ralph Markus Wirtz
发明人： Ralph Markus Wirtz
IPC分类号： C40B30/04 , C12Q1/68 , C12Q1/02
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/136
摘要： The invention provides novel compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and cancer. The invention further relates to genes that are differentially expressed in tissue of cancer patients versus those of normal “healthy” tissue. Differentially expressed genes for the identification of patients which are likely to respond to chemotherapy are also provided. The present invention relates to methods for prognosis the prediction of therapeutic success in cancer therapy. In a preferred embodiment of the invention it relates to methods for prediction of therapeutic success of combinations of signal transduction inhibitors, therapeutic antibodies, radio- and chemotherapy. The methods of the invention are based on determination of expression levels of 48 human genes which are differentially expressed prior to the onset of anti-cancer chemotherapy. The methods and compositions of the invention are most useful in the investigation of advanced colorectal cancer, but are useful in the investigation of other types of cancer and therapies as well.
摘要翻译：本发明提供了用于预测，诊断，预后，预防和治疗恶性肿瘤和癌症的新型组合物，方法和用途。本发明还涉及在癌症患者的组织中与正常“健康”组织的组织差异表达的基因。还提供了用于鉴定可能对化疗作出反应的患者的差异表达基因。本发明涉及预测癌症治疗中治疗成功的预测方法。在本发明的优选实施方案中，其涉及用于预测信号转导抑制剂，治疗性抗体，放射和化疗组合的治疗成功的方法。本发明的方法是基于在抗癌化疗开始之前差异表达的48个人基因的表达水平的确定。本发明的方法和组合物在晚期结肠直肠癌的研究中是最有用的，但在其他类型的癌症和疗法的研究中也是有用的。

7. 发明授权

US09683229B2 Matrix and method for purifying and/or isolating nucleic acids 有权
公开(公告)号：US09683229B2
公开(公告)日：2017-06-20
申请号：US14166759
申请日：2014-01-28
申请人： Ralph Markus Wirtz
发明人： Ralph Markus Wirtz
IPC分类号： C07H21/00 , C01G49/08 , C04B35/26 , C04B35/64 , C12N15/10
CPC分类号： C12N15/101 , C12N15/1006 , C12Q2563/137 , C12Q2563/143 , C12Q2563/155
摘要： The present invention relates to matrix materials suitable for use in purifying and/or isolating nucleic acids from a biological sample, which matrix comprises a surface comprising at least one element selected from the group consisting of Germanium, Tin and/or Lead, or at least one salt thereof, and methods related therewith.

8. 发明申请

US20120149027A1 Method for Determining the Risk of Metastasis as an Indicator for Diagnostic Imaging 审中-公开
标题翻译：确定转移风险作为诊断成像指标的方法
公开(公告)号：US20120149027A1
公开(公告)日：2012-06-14
申请号：US13391455
申请日：2010-06-29
申请人： Michael Untch , Ralph Markus Wirtz
发明人： Michael Untch , Ralph Markus Wirtz
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： The present invention pertains to the field of in vitro diagnostics and relates to a method for determining the risk of metastasis of a tumor, wherein a high risk of metastasis shows that subsequent examinations by means of imaging methods are indicated for the patient.
摘要翻译：本发明涉及体外诊断领域，涉及用于确定肿瘤转移风险的方法，其中高转移风险表明通过成像方法对患者进行后续检查。

9. 发明申请

US20110118129A1 METHOD FOR PREDICTING THERAPY RESPONSIVENESS IN BASAL LIKE TUMORS 审中-公开
标题翻译：在基础类似肿瘤中预防治疗反应的方法
公开(公告)号：US20110118129A1
公开(公告)日：2011-05-19
申请号：US12745668
申请日：2008-11-06
申请人： Ralph Markus Wirtz , Ralf Kronenwett
发明人： Ralph Markus Wirtz , Ralf Kronenwett
IPC分类号： C40B30/00 , C12Q1/68 , G01N33/53 , C07K16/00 , C07H21/04
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158
摘要： The present invention is related to a method for predicting a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining, on a non protein basis, the expression level of at least one gene of interest, said gene being correlated with the Estrogen receptor (ESR) status in the said sample, c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient from the outcome of the comparison in step (c). Moreover, the invention concerns nucleic acid molecules usefuls as primers and probes for detecting the expression of Her2-neu/ErbB2, MLHP and MMP7, respectively.
摘要翻译：本发明涉及一种用于预测患有或具有发展为肿瘤疾病的风险的患者的临床反应朝向至少一种给定治疗方式的方法，所述方法包括以下步骤：a）从所述的方法获得生物样品患者; b）在非蛋白质基础上确定至少一种目标基因的表达水平，所述基因与所述样品中的雌激素受体（ESR）状态相关，c）比较在（b）中确定的表达水平的模式）具有一个或几个表达水平的参考模式; 以及d）从步骤（c）中的比较结果预测所述患者中所述给定治疗模式的治疗成功。此外，本发明涉及分别用作检测Her2-neu / ErbB2，MLHP和MMP7表达的引物和探针的核酸分子。

10. 发明申请

US20090298061A1 Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapy 审中-公开
标题翻译：预防治疗成功的诊断方法，癌症治疗中的无复发和总体生存
公开(公告)号：US20090298061A1
公开(公告)日：2009-12-03
申请号：US11989830
申请日：2006-07-20
申请人： Ralph Markus Wirtz
发明人： Ralph Markus Wirtz
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12N15/1136 , C12Q2600/106 , C12Q2600/118 , C12Q2600/136
摘要： Described are 12 human genes which are differentially expressed in neoplastic tissues of patients responding well to treatment as compared to patients not responding well as determined by overall survival time in the non responding cohort. Moreover, methods for prognosis of the therapeutic success in cancer therapy are described. These methods are based on determination of expression levels of particular genes which are differentially expressed in cancer patients, preferably the genes encoding VEGFC, ERBB3 and Her2/neu, prior to the onset of anti-cancer chemotherapy. These methods are particularly useful in the investigation of advanced head and neck cancer, but are useful in the investigation of other types of cancer and therapies as well.
摘要翻译：描述了12个人类基因，其在患者的肿瘤组织中差异表达，与治疗反应良好的患者相比，无反应良好的患者，通过无反应队列中总生存时间确定。此外，描述了用于癌症治疗中治疗成功预后的方法。这些方法是基于癌症患者差异表达的特定基因的表达水平的确定，优选在编码VEGFC，ERBB3和Her2 / neu的基因之前，在抗癌化学疗法开始之前。这些方法在晚期头颈癌的研究中特别有用，但在其他类型的癌症和疗法的研究中也是有用的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式